Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

PHASE3CompletedINTERVENTIONAL
Enrollment

323

Participants

Timeline

Start Date

February 14, 2018

Primary Completion Date

December 12, 2018

Study Completion Date

July 16, 2019

Conditions
Anemia; Hemodialysis Dependent Chronic Kidney Disease
Interventions
DRUG

MT-6548

Oral tablet

DRUG

Darbepoetin alfa

Intravenous administration

DRUG

MT-6548-matching placebo

Oral tablet

DRUG

Darbepoetin alfa-matching placebo

Intravenous administration

Trial Locations (28)

Unknown

Research site, Aichi

Research site, Chiba

Research site, Fukui

Research site, Fukuoka

Research site, Fukushima

Research site, Gunma

Research site, Hiroshima

Research site, Hokkaido

Research site, Hyōgo

Research site, Ibaraki

Research site, Kagawa

Research site, Kagoshima

Research site, Kanagawa

Research site, Kumamoto

Research site, Kyoto

Research site, Miyagi

Research site, Nagano

Research site, Nagasaki

Research site, Okayama

Research site, Okinawa

Research site, Osaka

Research site, Ōita

Research site, Saitama

Research site, Shiga

Research site, Shizuoka

Research site, Tokushma

Research site, Tokyo

Research site, Yamagata

All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY